Document:

Employment Agreement dated as of November 15, 2002 - Michael G. Kelly, Ph. D.

 EXHIBIT 10.36 
  
 [GRAPHIC APPEARS HERE] 
  
 November 15, 2002 
  
 Michael G. Kelly, Ph.D., C.Chem., MRSC 
  
 Re: Employment Terms 
  
 Dear Mike: 
  
 I am extremely pleased to offer you the position of Senior Director, Chemistry. Everyone at Renovis is very enthusiastic about having you join us. I look forward to your
positive reply. Please review the following employment terms: 
  
 You will be
responsible for working as Senior Director, Chemistry and, at this time, will report to me. You will work at our facility located at 270 Littlefield, South San Francisco, CA. Of course, Renovis may change your position, reporting structure, duties,
and work location from time to time as it deems necessary. 
  
 Your compensation
will be $170,000 per year, less payroll deductions and all required withholdings. You will also be eligible for an annual bonus of up to 15% of base salary. As of your start date of no later than December 10th, 2002, you will be paid $7,083.33 before taxes and other deductions, semi-monthly on the fifteenth and last date of every month. In addition, you
will be granted an option to purchase 80,000 shares of the company’s common stock, as governed by the terms of the Company’s stock option plan, at a price to be determined by and subject to approval of the Company’s Board of
Directors. Your stock options will vest at a rate of 20,000 shares as of the first anniversary of your start date and 1666.67 shares per calendar month thereafter. 
  
 You will also be eligible for the following standard Company benefits: medical insurance, vacation, 401(k) plan, sick leave, and holidays.
(Please see attached summary). Details about these benefit plans are available for your review; however, please note that Renovis may modify compensation and benefits from time to time as it deems necessary. 
  
 To facilitate your joining Renovis, the company will reimburse you up to $50,000 in
relocation-related expenses. Typical relocation expenses include costs associated with the movement of household goods and automobile, temporary housing, and the down payment on the purchase of a home in the Bay Area. 
  
 As a Renovis employee, you will be expected to abide by Company rules and policies,
acknowledge in writing that you have read the Company’s Employee Handbook, and sign and comply with the attached Proprietary Information and Inventions Agreement which prohibits unauthorized use or disclosure of Renovis proprietary information.

  
 In your work for the Company, you will be expected not to use or disclose any
confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with
training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in 

 Michael G. Kelly, Ph.D., C.Chem., MRSC 
 November 15, 2002 
 Page 2 
  
 the public domain, or which is otherwise provided or developed by the Company. During our discussions about your proposed job duties, you assured us that you would be
able to perform those duties within the guidelines just described. 
  
 You agree
that you will not bring onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. 
  
 Normal business hours are from 8:30 a.m. to 5:30 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work
additional hours as required by the nature of your work assignments. 
  
 You may
terminate your employment with Renovis at any time and for any reason whatsoever simply by notifying Renovis. Likewise, Renovis may terminate your employment at any time and for any reason whatsoever, with or without cause or advance notice. This
at-will employment relationship cannot be changed except in writing signed by a Company officer. 
  
 This letter, together with your Proprietary Information and Inventions Agreement, forms the complete and exclusive statement of your employment agreement with Renovis. The employment terms in this letter supersede any
other agreements or promises made to you by anyone, whether oral or written. As required by law, this offer is subject to satisfactory proof of your right to work in the United States. 
  
 Please sign and date this letter, and return it to me by November 20, 2002, if you wish to accept employment at Renovis under the terms
described above. 
  
 I want you to know how enthusiastic we are to have you on the
Renovis team. I personally, and the rest of the team, look forward to working with you to make the drugs that will be great personal achievements and bring the company great success. I look forward to hearing back from you soon, and working together
starting soon thereafter. 
  
 Sincerely,

  

	 /s/ Corey Goodman

	 Corey Goodman, Ph.D.

	 President & Chief Executive Officer

	
	 Accepted:

	
	 /s/ [ILLEGIBLE]

	
	 11/18/02

	 Date

 Attachments: Proprietary Information and Inventions Agreement; Benefits SummaryEmployment Agreement dated as of May 1, 2003 - Michael G. Kelly, Ph.D.

 EXHIBIT 10.37 
  
 [GRAPHIC APPEARS HERE] 
  
 May 1, 2003 
  
 Michael Kelly, Ph.D. 
  
 Re: Amendment to
Renovis, Inc. Offer Letter 
  
 Dear Mike: 
  
 You and Renovis, Inc. (the “Company”) are parties to an offer letter dated
November 15, 2002 (the “Offer Letter”), which sets forth, among other things, the terms of your employment with the Company. The Company would like to amend the Offer Letter as provided below to provide you with certain severance benefits
in the event of a termination of your employment without Cause (as defined below) or your Constructive Termination (as defined below). This letter agreement supersedes any other agreement or policy to which the Company is a party with respect to any
severance benefits payable to you and any acceleration of vesting of your stock options or restricted stock as a result of your termination of employment. 
  
 1. Severance Benefits. 
  
 (a) Termination By The Company Without Cause. If your employment by the Company is terminated by the Company without Cause (as defined below), or
if there is a Constructive Termination (as defined below), at any time prior to the occurrence of a Change in Control or more than thirteen (13) months following the occurrence of a Change in Control, and if you provide the Company with a signed
general release of all claims, a form of which is set forth in Exhibit A hereto, the Company shall provide you with the following severance benefits: (1) continuation of your base salary for a period of six (6) months after your termination date at
the rate in effect immediately prior to your termination of employment, less applicable withholdings, payable in installments pursuant to the Company’s normal and customary payroll procedures; (2) for the period beginning on your date of
termination and ending on the date which is six (6) full months following your date of termination (or, if earlier, the date on which you accept employment with another employer that provides comparable benefits), the Company shall pay for and
provide you and your dependents with the same health benefits (e.g., medical and dental) to which you would have been entitled had you remained continuously employed by the Company during such period, including, if necessary, paying the costs
associated with continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”); and (3) on your date of termination, you shall immediately become vested with respect to those options to
purchase the Company’s capital stock that you then hold that would have vested during the six (6) month period following your date of termination and/or any restrictions with respect to restricted shares of the Company’s capital stock that
you then hold that would have vested during the six (6) month period following your date of termination shall immediately lapse. 

 You understand and agree that you shall not be entitled to any other severance pay, severance benefits, or any other
compensation or benefits other than as set forth in this paragraph in the event of such a termination, other than as required under applicable law. 
  
 (b) Termination By The Company With Cause Or Termination By You. If your employment by the Company is terminated by the Company with Cause, or if
you voluntarily terminate your employment with the Company (other than pursuant to a Constructive Termination (as defined below)), you shall not be entitled to any severance pay, severance benefits, or any compensation or benefits from the Company
whatsoever, other than as required under applicable law. 
  
 (c) Termination Following Change in Control. If your employment by the Company is terminated by the Company without Cause (as defined below), or if there is a Constructive Termination (as defined below), in each case at any time
within thirteen (13) months following the occurrence of a Change in Control, and if you provide the Company with a signed general release of all claims, a form of which is set forth in Exhibit A hereto, the Company shall provide you with the
following severance benefits: (1) a lump sum payment equal to twelve (12) months of your base salary at the rate in effect immediately prior to the Change in Control, less applicable withholdings, to be paid by the Company within ten (10) days of
your date of termination; (2) for the period beginning on your date of termination and ending on the date which is twelve (12) full months following your date of termination (or, if earlier, the date on which you accept employment with another
employer that provides comparable benefits), the Company shall pay for and provide you and your dependents with the same health benefits (e.g., medical and dental) to which you would have been entitled had you remained continuously employed by the
Company during such period, including, if necessary, paying the costs associated with continuation coverage pursuant to COBRA; and (3) on your date of termination, you shall immediately become 100% vested with respect to any options to purchase the
Company’s capital stock that you then hold and/or any restrictions with respect to restricted shares of the Company’s capital stock that you then hold shall immediately lapse, and you shall be entitled to exercise any such vested options
until the expiration date of such options set forth in the stock option agreement(s) pursuant to which they were granted; provided, however, that if you are terminated by the Company following the effective date of a Change in Control
described in clause (d)(2)(b) below but accept employment with the Company’s successor or acquirer within thirty (30) days after the effective date of the Change in Control on terms and conditions not less favorable to you than those contained
in the Offer Letter (as amended by this letter agreement), you shall not be entitled to any severance benefits under this clause (c); provided, further, however, that if your employment is thereafter terminated by the successor
or acquiror without Cause (as defined below), or if there is a Constructive Termination (as defined below), at any time within thirteen (13) months following the occurrence of the Change in Control, you shall be entitled to the severance benefits
described above in this clause (c). 
  
 You understand and agree that you shall
not be entitled to any other severance pay, severance benefits, or any other compensation or benefits other than as set forth in this paragraph in the event of such a termination, other than as required under applicable law. 

 (d) Definitions. 
  
 (1) Cause. For purposes of this letter agreement, the term “Cause” means: (i) theft, dishonesty or
falsification of any employment or Company records; (ii) malicious or reckless disclosure of the Company’s confidential or proprietary information; (iii) commission of any immoral or illegal act or any gross or willful misconduct, where the
Company reasonably determines that such act or misconduct has (A) seriously undermined the ability of the Company’s management to entrust you with important matters or otherwise work effectively with you, (B) contributed to the Company’s
loss of significant revenues or business opportunities, or (C) significantly and detrimentally effected the business or reputation of the Company or any of its subsidiaries; and/or (iv) the failure or refusal by you to work diligently to perform
tasks or achieve goals reasonably requested by the Board, provided such failure or refusal continues after the receipt of reasonable notice in writing of such failure or refusal and an opportunity to correct the problem. “Cause” shall not
mean a physical or mental disability. 
  
 (2) Change in
Control. For purposes of this letter agreement, the term “Change in Control” means the consummation of any of the following transactions: 
  
 a. the closing of a business combination (such as a merger or consolidation) of the Company with any other corporation or other type of business
entity (such as a limited liability company), other than a business combination which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being
converted into voting securities of the surviving entity) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such controlling surviving entity outstanding immediately after such business
combination; or 
  
 b. the sale, lease, exchange or other
transfer or disposition by the Company of all or substantially all (more than seventy percent (70%)) of the Company’s assets by value; or 
  
 c. an acquisition of any voting securities of the Company by any “person” (as the term “person” is used for purposes of
Section 13(d) or Section 14(d) of the Securities Exchange Act of 1934, as amended (the “1934 Act”)) immediately after which such person has “beneficial ownership” (within the meaning of Rule 13d-3 promulgated under the 1934 Act)
of fifty percent (50%) or more of the combined voting power of the Company’s then outstanding voting securities. 
  
 (3) Constructive Termination. For purposes of this letter agreement, the term “Constructive Termination” means your resignation within
sixty (60) days of one or more of the following events which remains uncured thirty (30) days after your delivery of written notice thereof: 

 a. the delegation to you of duties or the reduction of your duties, either of which substantially
reduces the nature, responsibility, or character of your position immediately prior to such delegation or reduction; 
  
 b. a material reduction by the Company in your base salary in effect immediately prior to such reduction; 
  
 c. a material reduction by the Company in the kind or level of
employee benefits or fringe benefits to which you were entitled prior to such reduction; or the taking of any action by the Company that would adversely affect your participation in any plan, program or policy generally applicable to employees of
equivalent seniority; and 
  
 d. the Company’s
requiring you to relocate your office to a place more than forty (40) miles from its present location (except that required travel on the Company’s business to an extent substantially consistent with your present business travel obligations
shall not be considered a relocation). 
  
 2. Effect of Amendment. Except
as specifically amended above, the Offer Letter shall remain in full force and effect and is hereby ratified and confirmed. 
  
 3. Entire Agreement. This letter agreement and Exhibit A hereto, together with the Offer Letter, constitute the entire agreement between you and the Company
relating to the terms and conditions of your employment specified herein and therein. 
  
 If the terms of this letter agreement are acceptable to you, please sign below and return this letter to Paula Serbin. 
  

	 Very truly yours,

	
	Renovis, Inc.
	
	 /s/ Corey Goodman

	 Corey Goodman, Ph.D.

	 President and Chief Executive Officer

  

	Accepted and Agreed to by:
	
	 /s/ Michael Kelly

	 Michael Kelly, Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]